Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
IBER.WS
IBER.WS was delisted on the 15th of February, 2023.
36 hedge funds and large institutions have $2.08M invested in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
9% more funds holding
Funds holding: 33 → 36 (+3)
14% less capital invested
Capital invested by funds: $2.43M → $2.08M (-$351K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$31K |
| 2 |
EFI
EHP Funds Inc
Toronto,
Canada
|
+$16.3K |
| 3 |
CAC
Cowen and Company
New York
|
+$15.9K |
| 4 |
AGM
Alpine Global Management
New York
|
+$10.6K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$9.24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$52.5K |
| 2 |
PI
PEAK6 Investments
Chicago,
Illinois
|
-$5K |
| 3 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
-$611 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$190 |
IBER.WS Hedge Fund Activity: Q2 2022 in Review
36 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) for Q2 2022, worth a combined $2.08M — down 14% from $2.43M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IBER.WS positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Clear Street, opening a new position worth an estimated $31K. The largest seller was Citadel Advisors, cutting an estimated $52.5K.
- 36 institutional investors held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) as of Q2 2022, up from 33 in Q1 2022.
- Funds reported $2.08M of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share stock for Q2 2022, down 14% quarter-over-quarter.
- 6 funds opened new Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share positions in Q2 2022 and 3 closed out, a net change of +3 holders.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share buyer in Q2 2022 was Clear Street, an estimated $31K added.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share seller in Q2 2022 was Citadel Advisors, an estimated $52.5K sold.
Based on aggregated 13F filings for Q2 2022.